Getting More From Biomedical Innovation

Getting More From Biomedical Innovation

Share

Details

In 2018 the FDA approved a record number of new products, but pharmaceutical R&D returns have fallen to their lowest level in nine years. Biotech IPOs are still strong in an overall weakening market, but federal investment in biomedical R&D, which feeds the product and start-up pipeline, has declined almost 20 percent in real terms since 2003. How should we collectively be measuring the success of our R&D investments, and how are investment behaviors incentivized across the biomedical ecosystem? Can the economic and societal benefits of biomedical innovation outputs—from basic science to patient access—be measured from the patient perspective?

Custom Author Text

Moderator

Esther Krofah
Senior Director, FasterCures, a center of the Milken Institute

 

Speakers

Amitabh Chandra
McCance Family Professor of Business Administration, Harvard University

 

Kafui Dzirasa
K. Ranga Rama Krishnan Associate Professor, Psychiatry, Duke University

 

Pat Furlong
President and CEO, Parent Project Muscular Dystrophy

 

Christopher Hite
Vice Chairman, Global Head of Healthcare, Citi

 

Pablo Legorreta
Founder and CEO, Royalty Pharma

 

Tags
Tags
Published May 3, 2019